Return to Home Incidence > Table > Interpret

Interpretation of Incidence Rates Data

Incidence Rate Report by State

Lung & Bronchus (All Stages^), 2018-2022

Black Non-Hispanic, Both Sexes, All Ages

Sorted by CI*Rank

Explanation of Column Headers
Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.

Recent Trends - This is an interpretation of the AAPC/APC:

AAPC/APC (95% Confidence Interval) - the change in rate over time


Other Notes


Line by Line Interpretation of the Report


Wisconsin2


Iowa7


Kentucky7


Missouri2


Arkansas2


Mississippi2


Ohio2


Illinois7


West Virginia2


Pennsylvania2


Louisiana7


Oklahoma2


Indiana2


Nebraska2


Michigan2


North Carolina2


District of Columbia2


Idaho7


Kansas2


Tennessee2


Minnesota2


Texas7


Washington1


Virginia2


Connecticut7


Alabama2


South Carolina2


Georgia7


Rhode Island2


Maryland2


California7


Delaware2


New Jersey7


Nevada2


Oregon2


New York7


Arizona2


Massachusetts2


Alaska2


Florida2


Utah7


Colorado2


New Hampshire2


New Mexico7


Maine2


Hawaii7


Montana2 North Dakota2 South Dakota2 Vermont2 Wyoming2 Puerto Rico2


Notes:
Created by statecancerprofiles.cancer.gov on 03/26/2026 12:05 am.

State Cancer Registries may provide more current or more local data.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (SEER areas use 20 age groups and NPCR areas use 19 age groups). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates and trends are computed using different standards for malignancy. For more information see malignant.html.

^ All Stages refers to any stage. Due to changes in stage coding, Combined Summary Stage with Expanded Regional Codes (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. The rates used in CI*Rank are all age-adjusted to the 2000 US standard population using 19 age groups for SEER and NPCR areas. More information about methodology can be found on the CI*Rank website.

Source: SEER and NPCR data. For more specific information please see the table.

* Data has been suppressed to ensure confidentiality and stability of rate estimates. Counts are suppressed if fewer than 16 records were reported in a specific area-sex-race category.

¶¶¶ Data for Puerto Rico is only available for All Races (includes Hispanics). For more information see data not available.

Data for United States does not include Puerto Rico.

CI*Rank data for Puerto Rico is not available.